Dr. Georg S. Kobinia

Dr. Georg S. Kobinia |Clyto Access





Title: Treatment of Spinal cord injury with autologous bone marrow-derived mononuclear cells.


Background: As many as 500 000 people suffer spinal cord injury each year, the condition affects mainly the most productive sector of the population(1). Despite advances in pre-hospital care, medical and surgical management, and rehabilitation approaches, many SCI sufferers still experience substantial neurological disability(2). Since the last decade the use of stem cell therapies, in particular bone marrow-derived stem cells that include hematopoietic and mesenchymal stem cells had been promoted. This cells secrete all kind of factors, which influence the direct environment of injured cells inducing neuroprotection by inflammation suppression together with neuroregeneration, allowing the reconstruction of totally damaged tissues and preventing  partially damaged cells from evolving to cell demise(3,4). The mechanisms known are the stimulation of neovascularization and increase oxygenation, transdifferentiate into specific neuronal cells, promotion of synaptic connections and promotion of neuroplasticity(5–8). Several studies had been publish with positive results in acute and chronic patients(9).

Objective: Our principal aim was to prove the safety and effectiveness of the Neuron Point-Of-Care Stem Cell Therapy (N-POCST), an autologous bone marrow-derived mononuclear cells transplantation and bone marrow-derived plasma after an on-site separation by a closed system and reinfusion in the cerebrospinal fluid by a regular lumbar puncture. The study was performed under the condition of “Unproven intervention in Clinical Practice” described in the Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association of Helsinki Declaration.

Method: The study was an open label pilot study in 61 patients with spinal cord injury. The primary endpoint was to document adverse effects and establish the safety profile of the intervention. The secondary endpoint was to evaluate the effects of N-POCST on functional impairment.

Results: After 6 months the preliminary results from patients with complete SCI (n=16) showed that 62% improved muscular strength, 50% improved spasticity, 50% improved sensibility 37% improved bladder control and 93% referred a better general health status.

Conclusions: The method is safe and feasible and consistent with the effectiveness published before related to cell therapies. ,

Related Conferences :

Global Forum on Transplantation Research and Technologies